C19orf47 exon 9–AKT2 exon 3 chimeric RNA (C19orf47-AKT2)

C19orf47e9–AKT2e3 is a chimeric RNA transcript formed by the fusion of exon 9 of the C19orf47 gene and exon 3 of the AKT2 gene, primarily identified as a recurrent alteration in high-grade serous ovarian cancer (HGSOC). This fusion typically arises from genomic rearrangements or read-through transcription between the two adjacent genes located on chromosome 19q13.2. The resulting chimeric RNA encodes a fusion protein that preserves the functional kinase domain of AKT2, leading to its constitutive activation and the subsequent hyperactivation of the PI3K/AKT signaling pathway. This aberrant signaling drives critical hallmarks of cancer, including enhanced cell proliferation, survival, and metabolic alterations. As a recurrent genetic driver in ovarian cancer, the C19orf47-AKT2 fusion serves as both a potential diagnostic biomarker and a therapeutic target. Pharmacological intervention typically involves the use of AKT inhibitors to suppress the constitutive signaling driven by the fusion protein, offering a precision medicine approach for patients harboring this specific molecular profile.

Other names

C19orf47-AKT2 fusion transcriptC19orf47e9-AKT2e3C19orf47-AKT2 chimeric transcriptPIGU-AKT2 fusion

The chimeric RNA encodes a fusion protein that retains the functional kinase domain of AKT2; pharmacological agents target this molecule by inhibiting the constitutive kinase activity of the AKT2 portion, thereby blocking downstream oncogenic signaling pathways.